Sensitising PDAC to Gemcitabine by Suppressing NF-κB Pathway and Enhancing Apoptosis

<b>Background/Objectives:</b> Pancreatic ductal adenocarcinoma (PDAC) exhibits poor clinical response to gemcitabine, largely due to intrinsic and acquired mechanisms of chemoresistance. Identifying agents capable of enhancing gemcitabine efficacy without increasing cytotoxicity remains an unmet the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Enhui Jin, Maria Rita Gil da Silva Simões, Steve O’Hagan, Enzhi Jin, Philip J. Day
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-01-01
Edice:	Pharmaceuticals
Témata:	drug sensitiser small molecule PDAC solid tumour gemcitabine NF-κB signalling
On-line přístup:	https://www.mdpi.com/1424-8247/19/2/243
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!